Avidity Biosciences, INC DEF 14A proxy statements

Avidity Biosciences has adjourned its Special Stockholder Meeting to February 26, 2026, to finalize conditions for its SpinCo distribution, a prerequisite for the expected February 27, 2026 merger closing with Novartis.

Novartis AG plans to acquire Avidity Biosciences, Inc., which will first spin off its early-stage precision cardiology programs into a new independent entity, Atrium Therapeutics, Inc.

Novartis AG plans to acquire Avidity Biosciences, Inc., while Avidity's early-stage precision cardiology programs will be spun off into a new independent entity, Atrium Therapeutics, Inc.

Avidity Biosciences, Inc. announced early termination of the HSR waiting period for its merger with Novartis AG and accelerated executive compensation to mitigate tax impacts.

Novartis AG plans to acquire Avidity Biosciences for $12 billion, with Avidity spinning off its early-stage precision cardiology programs into a new independent entity, SpinCo.

Novartis AG will acquire Avidity Biosciences' neuroscience pipeline and RNA platform, while Avidity's early-stage cardiology programs will be spun off into a new independent company.

Avidity Biosciences announces its acquisition by Novartis for approximately $12 billion, plans a spin-off of its early-stage precision cardiology programs, and reports strong Q3 2025 financial results with positive clinical data.

Avidity Biosciences announces a definitive merger agreement with Novartis, spinning off its early-stage precision cardiology programs.

Novartis AG will acquire Avidity Biosciences' neuroscience programs and RNA-targeting platform, while Avidity's early-stage precision cardiology programs will be spun off into a new public company, SpinCo.

Novartis AG has agreed to acquire Avidity Biosciences' neuroscience pipeline and RNA-targeting platform for $12 billion, while Avidity's early-stage cardiology programs will be spun off into a new publicly traded company, SpinCo.

Novartis AG will acquire Avidity Biosciences for $72.00 per share in cash, valuing the company at $12.0 billion, while Avidity's early-stage cardiology programs will be spun off into a new publicly traded entity, SpinCo.

Avidity Biosciences has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting on company matters.

Avidity Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory vote.

Avidity Biosciences announces the appointment of Simona Skerjanec as an independent director and Troy Wilson to the Human Capital Management Committee, effective May 14, 2024.

Avidity Biosciences has filed a definitive proxy statement with the SEC.

Avidity Biosciences will hold its annual stockholders meeting virtually on June 13, 2024, to vote on director elections, auditor ratification, and executive compensation.